Published in Cancer on June 01, 2003
A review of clinical and molecular prognostic factors in osteosarcoma. J Cancer Res Clin Oncol (2007) 2.07
Integrative analysis reveals the direct and indirect interactions between DNA copy number aberrations and gene expression changes. Bioinformatics (2008) 1.49
Correlation between MMPs and their inhibitors in breast cancer tumor tissue specimens and in cell lines with different metastatic potential. BMC Cancer (2009) 1.29
Metastasis suppressors and the tumor microenvironment. Cancer Microenviron (2008) 1.07
The metalloproteinase inhibitor Reck is essential for zebrafish DRG development. Development (2012) 1.02
Inflammation and breast cancer: metalloproteinases as common effectors of inflammation and extracellular matrix breakdown in breast cancer. Breast Cancer Res (2008) 0.99
TIMP-2 upregulates RECK expression via dephosphorylation of paxillin tyrosine residues 31 and 118. Oncogene (2006) 0.98
The Kazal motifs of RECK protein inhibit MMP-9 secretion and activity and reduce metastasis of lung cancer cells in vitro and in vivo. J Cell Mol Med (2008) 0.93
Correlation of matrix metalloproteinase suppressor genes RECK, VEGF, and CD105 with angiogenesis and biological behavior in esophageal squamous cell carcinoma. World J Gastroenterol (2007) 0.91
The silencing of RECK gene is associated with promoter hypermethylation and poor survival in hepatocellular carcinoma. Int J Biol Sci (2012) 0.87
Expression of RECK and MMP-2 in salivary adenoid cystic carcinoma: Correlation with tumor progression and patient prognosis. Oncol Lett (2014) 0.86
HPV16 oncoproteins induce MMPs/RECK-TIMP-2 imbalance in primary keratinocytes: possible implications in cervical carcinogenesis. PLoS One (2012) 0.86
MicroRNA-135b, a HSF1 target, promotes tumor invasion and metastasis by regulating RECK and EVI5 in hepatocellular carcinoma. Oncotarget (2015) 0.85
Expression and localisation of the new metalloproteinase inhibitor RECK (reversion inducing cysteine-rich protein with Kazal motifs) in inflamed synovial membranes of patients with rheumatoid arthritis. Ann Rheum Dis (2004) 0.84
Expression of the reversion-inducing cysteine-rich protein with Kazal motifs and matrix metalloproteinase-14 in neuroblastoma and the role in tumour metastasis. Int J Exp Pathol (2010) 0.81
Zinc-chelation contributes to the anti-angiogenic effect of ellagic acid on inhibiting MMP-2 activity, cell migration and tube formation. PLoS One (2011) 0.79
Candidate prognostic markers in breast cancer: focus on extracellular proteases and their inhibitors. Breast Cancer (Dove Med Press) (2014) 0.77
Reversion-inducing cysteine-rich protein with Kazal motifs gene expression and its clinical significance in peripheral T-cell lymphoma. Oncol Lett (2013) 0.77
Reversion-inducing cysteine-rich protein with kazal motifs and matrix metalloproteinase-9 are prognostic markers in skull base chordomas. Neurosurg Rev (2009) 0.77
Differential expression of degradome components in cutaneous squamous cell carcinomas. Mod Pathol (2013) 0.77
Isolation and characterization of novel RECK tumor suppressor gene splice variants. Oncotarget (2015) 0.76
RECK Gene Polymorphism is Associated with Susceptibility and Prognosis of Wilms' Tumor in Chinese Children. Med Sci Monit (2015) 0.75
MicroRNA-15b regulates reversion-inducing cysteine-rich protein with Kazal motifs (RECK) expression in human uterine leiomyoma. Reprod Biol Endocrinol (2016) 0.75
RECK is not an independent prognostic marker for breast cancer. BMC Cancer (2015) 0.75
miR-15a-5p, A Novel Prognostic Biomarker, Predicting Recurrent Colorectal Adenocarcinoma. Mol Diagn Ther (2017) 0.75
Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med (2004) 8.91
Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis. Hum Mol Genet (2008) 3.93
Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet (2011) 3.76
Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. Am J Hum Genet (2008) 3.41
High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer. N Engl J Med (2003) 3.15
Rare deletions at 16p13.11 predispose to a diverse spectrum of sporadic epilepsy syndromes. Am J Hum Genet (2010) 2.61
Multicenter validation of a gene expression-based prognostic signature in lymph node-negative primary breast cancer. J Clin Oncol (2006) 2.48
Exposure to diagnostic radiation and risk of breast cancer among carriers of BRCA1/2 mutations: retrospective cohort study (GENE-RAD-RISK). BMJ (2012) 2.44
Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J Natl Cancer Inst (2002) 2.25
Fatigue and relating factors in high-risk breast cancer patients treated with adjuvant standard or high-dose chemotherapy: a longitudinal study. J Clin Oncol (2005) 2.14
Vascular endothelial growth factor is associated with the efficacy of endocrine therapy in patients with advanced breast carcinoma. Cancer (2003) 1.74
Common genetic variation and susceptibility to partial epilepsies: a genome-wide association study. Brain (2010) 1.67
Tissue inhibitors of metalloproteinase expression in human breast cancer: TIMP-3 is associated with adjuvant endocrine therapy success. J Pathol (2004) 1.67
Carbonic anhydrase-9 expression levels and prognosis in human breast cancer: association with treatment outcome. Br J Cancer (2003) 1.63
Mammaglobin is associated with low-grade, steroid receptor-positive breast tumors from postmenopausal patients, and has independent prognostic value for relapse-free survival time. J Clin Oncol (2004) 1.55
AUY954, a selective S1P(1) modulator, prevents experimental autoimmune neuritis. J Neuroimmunol (2009) 1.50
Characterization of Mca-Lys-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2, a fluorogenic substrate with increased specificity constants for collagenases and tumor necrosis factor converting enzyme. Anal Biochem (2004) 1.50
Decreased prolactin response to hypoglycaemia in patients with rheumatoid arthritis: correlation with disease activity. Ann Rheum Dis (2004) 1.40
Survivin is an independent prognostic marker for risk stratification of breast cancer patients. Clin Chem (2004) 1.36
Expression of the transcription factor Ets-1 is an independent prognostic marker for relapse-free survival in breast cancer. Oncogene (2002) 1.34
Screening for Lrrk2 G2019S and clinical comparison of Tunisian and North American Caucasian Parkinson's disease families. Mov Disord (2007) 1.32
Increased neurofilament light chain blood levels in neurodegenerative neurological diseases. PLoS One (2013) 1.32
T-cell response against varicella-zoster virus in fingolimod-treated MS patients. Neurology (2013) 1.22
Antigen-specific adaptive immune responses in fingolimod-treated multiple sclerosis patients. Ann Neurol (2011) 1.15
Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients. Eur J Cancer (2013) 1.12
Clinical features of Parkinson disease patients with homozygous leucine-rich repeat kinase 2 G2019S mutations. Arch Neurol (2006) 1.09
A comparative study of CSF neurofilament light and heavy chain protein in MS. Mult Scler (2013) 1.09
Cyclin-E is a strong predictor of endocrine therapy failure in human breast cancer. Oncogene (2003) 1.08
Prospective multicenter validation of the independent prognostic value of the mitotic activity index in lymph node-negative breast cancer patients younger than 55 years. J Clin Oncol (2005) 1.08
Anabolic and catabolic responses of human articular chondrocytes to varying oxygen percentages. Arthritis Res Ther (2010) 1.07
A highly sensitive electrochemiluminescence immunoassay for the neurofilament heavy chain protein. J Neuroimmunol (2010) 1.05
Altered microRNA expression in B lymphocytes in multiple sclerosis: towards a better understanding of treatment effects. Clin Immunol (2012) 1.04
(11)C-PBR28 imaging in multiple sclerosis patients and healthy controls: test-retest reproducibility and focal visualization of active white matter areas. Eur J Nucl Med Mol Imaging (2015) 1.03
Immunomodulatory effects of etanercept in a model of brain injury act through attenuation of the acute-phase response. J Neurochem (2007) 1.02
Stress and outcome success in IVF: the role of self-reports and endocrine variables. Hum Reprod (2005) 1.01
Respiratory failure due to bilateral diaphragm palsy as an early manifestation of ALS. Med Sci Monit (2003) 1.01
Levels of matrix metalloproteinase-9 within cerebrospinal fluid in a rabbit model of coccidioidal meningitis and vasculitis. J Infect Dis (2002) 1.00
Increased expression of matrix metalloproteinases in mononuclear blood cells of normal-tension glaucoma patients. J Glaucoma (2004) 1.00
The prognostic value of vascular endothelial growth factor in 574 node-negative breast cancer patients who did not receive adjuvant systemic therapy. Br J Cancer (2002) 0.99
Multiple sclerosis as a generalized CNS disease--comparative microarray analysis of normal appearing white matter and lesions in secondary progressive MS. J Neuroimmunol (2004) 0.97
Isolation of microarray-grade total RNA, microRNA, and DNA from a single PAXgene blood RNA tube. J Mol Diagn (2007) 0.96
Endothelial cell barrier impairment induced by glioblastomas and transforming growth factor beta2 involves matrix metalloproteinases and tight junction proteins. J Neuropathol Exp Neurol (2008) 0.95
Fertility in patients with congenital adrenal hyperplasia. J Pediatr Endocrinol Metab (2006) 0.94
Physical activity and the risk of breast cancer in BRCA1/2 mutation carriers. Breast Cancer Res Treat (2009) 0.94
Transsphenoidal pituitary surgery via the endoscopic technique: results in 35 consecutive patients with Cushing's disease. Eur J Endocrinol (2006) 0.94
Learning from nature: pregnancy changes the expression of inflammation-related genes in patients with multiple sclerosis. PLoS One (2010) 0.92
Matrix metalloproteinase inhibition lowers mortality and brain injury in experimental pneumococcal meningitis. Infect Immun (2014) 0.92
Risk factors for non-sentinel lymph node metastases in patients with breast cancer. The outcome of a multi-institutional study. Ann Surg Oncol (2006) 0.91
Metabolic profile of the hippocampus of Zucker Diabetic Fatty rats assessed by in vivo 1H magnetic resonance spectroscopy. NMR Biomed (2004) 0.91
Matrix metalloproteinases in neuromuscular disease. Muscle Nerve (2007) 0.91
Monitoring hypoxia and vasculature during bevacizumab treatment in a murine colorectal cancer model. Contrast Media Mol Imaging (2014) 0.90
Gene expression in cortex and hippocampus during acute pneumococcal meningitis. BMC Biol (2006) 0.90
Validation study suggested no differential misclassification of self-reported mammography history in BRCA1/2 mutation carriers. J Clin Epidemiol (2011) 0.89
Predictive impact of urokinase-type plasminogen activator: plasminogen activator inhibitor type-1 complex on the efficacy of adjuvant systemic therapy in primary breast cancer. Cancer Res (2004) 0.89
Serial plasma concentrations of atrial natriuretic peptide, plasma renin activity, aldosterone, and antidiuretic hormone in neonates on extracorporeal membrane oxygenation. ASAIO J (2002) 0.88
Sperm integrity pre- and post-chemotherapy in men with testicular germ cell cancer. Hum Reprod (2006) 0.88
Anti-interferon-beta neutralising activity is not entirely mediated by antibodies. J Neuroimmunol (2007) 0.88
Measurement of plasminogen activator system components in plasma and tumor tissue extracts obtained from patients with breast cancer: an EORTC Receptor and Biomarker Group collaboration. Oncol Rep (2005) 0.88
Impaired Sertoli cell function in males diagnosed with Noonan syndrome. J Pediatr Endocrinol Metab (2008) 0.88
Pooled analysis of prognostic impact of uPA and PAI-1 in breast cancer patients. Thromb Haemost (2003) 0.87
Pro-invasive gene regulating effect of irradiation and combined temozolomide-radiation treatment on surviving human malignant glioma cells. Eur J Pharmacol (2006) 0.87
Fetal growth and the function of the adrenal cortex in preterm infants. J Clin Endocrinol Metab (2002) 0.87
An ELISA avoiding interference by heterophilic antibodies in the measurement of components of the plasminogen activation system in blood. J Immunol Methods (2002) 0.86
Predicting early failure after adjuvant chemotherapy in high-risk breast cancer patients with extensive lymph node involvement. Clin Cancer Res (2004) 0.86
Antimyelin antibodies in clinically isolated syndromes correlate with inflammation in MRI and CSF. J Neurol (2007) 0.86
Neutralizing antibodies against IFN-beta in multiple sclerosis: antagonization of IFN-beta mediated suppression of MMPs. Brain (2003) 0.85
Identification and characterization of multiple species of tenascin-X in human serum. FEBS J (2007) 0.84
Immunoglobulin M oligoclonal bands: biomarker of targetable inflammation in primary progressive multiple sclerosis. Ann Neurol (2014) 0.84
Reliability of self-reported diagnostic radiation history in BRCA1/2 mutation carriers. Eur J Epidemiol (2010) 0.84
Expression and localisation of the new metalloproteinase inhibitor RECK (reversion inducing cysteine-rich protein with Kazal motifs) in inflamed synovial membranes of patients with rheumatoid arthritis. Ann Rheum Dis (2004) 0.84
The prognostic value of proliferation in lymph-node-negative breast cancer patients is age dependent. Eur J Cancer (2006) 0.83
Interferon beta 1b following natalizumab discontinuation: one year, randomized, prospective, pilot trial. BMC Neurol (2013) 0.83
High survivin predicts a poor response to endocrine therapy, but a good response to chemotherapy in advanced breast cancer. Breast Cancer Res Treat (2006) 0.83
Hypothalamic-pituitary-adrenal axis activity in patients with rheumatoid arthritis. Clin Exp Rheumatol (2005) 0.83
Monitoring of menstrual cycles, ovulation, and adrenal suppression by saliva sampling in female patients with 21-hydroxylase deficiency. Fertil Steril (2003) 0.83
Inhibition of protein kinase CbetaII increases glucose uptake in 3T3-L1 adipocytes through elevated expression of glucose transporter 1 at the plasma membrane. Mol Endocrinol (2003) 0.83
Menopausal status and adjuvant hormonal therapy for breast cancer patients: a practical guideline. Crit Rev Oncol Hematol (2012) 0.82
Optimal age to start preventive measures in women with BRCA1/2 mutations or high familial breast cancer risk. Int J Cancer (2013) 0.82
Phlorizin treatment prevents the decrease in plasma insulin levels but not the progressive histopathological changes in the pancreatic islets during aging of Zucker diabetic fatty rats. J Endocrinol Invest (2003) 0.82
The prognostic value of the mitotic activity index in patients with primary breast cancer who were not treated with adjuvant systemic therapy. Breast Cancer Res Treat (2003) 0.81
Glial activation in the early stages of brain metastasis: TSPO as a diagnostic biomarker. J Nucl Med (2014) 0.81
Cytosolic persistence of mouse brain CYP1A1 in chronic heme deficiency. Biol Chem (2005) 0.81
Neurofilament heavy chain and heat shock protein 70 as markers of seizure-related brain injury. Epilepsia (2012) 0.81
Matrix metalloproteinases-9 and -2 in secondary vasculitic neuropathies. Acta Neuropathol (2002) 0.80